Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-12-03EMA Authorised: Ontozry (cenobamate) — Angelini Pharma S.p.A
The EMA has authorised Ontozry (cenobamate) from Angelini Pharma S.p.A. for epilepsy in the European Union, with decision dated 17 November …
-
EMA approval · 2025-12-02EMA Authorised: Pregabalin Sandoz (pregabalin) — Sandoz GmbH
The EMA authorised the Sandoz generic pregabalin product for anxiety disorders, neuralgia, and epilepsy.
-
FDA approval · 2025-11-25FDA Approved: PERAMPANEL — Original Application (Novadoz Pharmaceuticals LLC)
The FDA approved the original application for a generic form of perampanel from Novadoz Pharmaceuticals LLC.
-
FDA approval · 2025-11-25FDA Approved: PERAMPANEL — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic version of perampanel (PERAMPANEL) under an original ANDA, expanding access to an adjunc…
-
FDA approval · 2025-11-24FDA Approved: GABAPENTIN — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for gabapentin from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (ANDA211314).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-11-21FDA Approved: LEVETIRACETAM — Original Application (Guardian Drug Company)
FDA approval of the original abbreviated new drug application for LEVETIRACETAM (Guardian Drug Company) establishing its generic status.
-
FDA approval · 2025-11-13FDA Approved: BRIVARACETAM — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved an original application for brivaracetam as a generic drug, with Novadoz Pharmaceuticals LLC listed as the applicant. The appro…
-
EMA approval · 2025-11-05EMA Authorised: Pregabalin Viatris Pharma (previously Pregabalin Pfizer) (pregabalin) — Viatris Healthcare Limited
The EMA authorised a pregabalin product under the Viatris Pharma marketing authorisation (formerly Pfizer), for anxiety disorders and epilep…
-
FDA approval · 2025-10-23FDA Approved: TOPIRAMATE — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for Topiramate by Teva Pharmaceuticals under the generic drug pathway.
-
EMA approval · 2025-10-22EMA Authorised: Zonisamide Viatris (previously Zonisamide Mylan) (zonisamide) — Viatris Limited
EMA authorised zonisamide for epilepsy under the Viatris Limited marketing authorisation. The product was previously marketed as Zonisamide …
-
FDA approval · 2025-10-16FDA Approved: ZTALMY — Supplemental Application (Immedica Pharma US Inc)
FDA approves a supplemental application for ZTALMY (ganaxolone) submitted by Immedica Pharma US Inc.
-
FDA approval · 2025-10-15FDA Approved: LACOSAMIDE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for lacosamide, a generic anticonvulsant, under the ANDA framework. The notice…
-
FDA approval · 2025-10-07FDA Approved: TOPIRAMATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental ANDA for Topiramate from Aurobindo Pharma Limited.
-
FDA approval · 2025-10-07FDA Approved: LAMOTRIGINE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic lamotrigine as an original application, authorizing the first generic version of lamotri…
-
FDA approval · 2025-10-01FDA Approved: PREGABALIN — Supplemental Application (Creekwood Pharmaceuticals LLC)
The FDA approved a supplemental application for pregabalin from Creekwood Pharmaceuticals LLC under ANDA213423.
-
FDA approval · 2025-09-30FDA Approved: TEGRETOL XR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tegretol XR (carbamazepine) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2025-09-29FDA Approved: LAMOTRIGINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Lamotrigine from Zydus Pharmaceuticals USA Inc., resulting in clearance for a generic lamotrigin…
-
FDA approval · 2025-09-23FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2025-09-23FDA Approved: PRIMIDONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Primidone (generic) from Actavis Pharma, Inc., under ANDA083551.
-
FDA approval · 2025-09-19FDA Approved: GABAPENTIN — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved ScieGen Pharmaceuticals' original application for a generic gabapentin, enabling a generic version to be marketed for the same …
-
FDA approval · 2025-09-17FDA Approved: OXCARBAZEPINE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for Oxcarbazepine filed by Glenmark Pharmaceuticals Inc., USA.
-
FDA approval · 2025-09-16FDA Approved: SUBVENITE — Original Application (OWP Pharmaceuticals, Inc.)
The FDA approved SUBVENITE (lamotrigine) through an Original Application filed by OWP Pharmaceuticals, Inc.
-
FDA approval · 2025-09-16FDA Approved: OXCARBAZEPINE — Supplemental Application (EPIC PHARMA, LLC)
FDA approved a supplemental application for oxcarbazepine submitted by Epic Pharma, LLC, authorizing a generic formulation under ANDA 215332…
-
FDA approval · 2025-09-05FDA Approved: GABARONE — Supplemental Application (INA Pharmaceutics Inc.)
FDA approved a supplemental application for GABARONE (gabapentin) by INA Pharmaceutics Inc. under ANDA211313. This action typically reflects…
-
FDA approval · 2025-09-03FDA Approved: VIGAFYDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for VIGAFYDE (vigabatrin) submitted by Upsher-Smith Laboratories, LLC. The action updates the produc…